76 related articles for article (PubMed ID: 11694130)
1. From the Food and Drug Administration.
Schwetz BA
JAMA; 2001 Nov; 286(17):2085. PubMed ID: 11694130
[No Abstract] [Full Text] [Related]
2. Drug combination approved for advanced breast cancer.
FDA Consum; 2002; 36(1):5. PubMed ID: 11881602
[No Abstract] [Full Text] [Related]
3. Improved survival in advanced breast cancer with docetaxel and capecitabine in combination: biological synergy or an artefact of trial design?
Wright TL; Twelves CJ
Eur J Cancer; 2002 Oct; 38(15):1957-60. PubMed ID: 12376198
[No Abstract] [Full Text] [Related]
4. NICE recommends new treatment for breast and bowel cancer.
Mayor S
BMJ; 2003 May; 326(7400):1166. PubMed ID: 12775610
[No Abstract] [Full Text] [Related]
5. The search for enhanced therapeutic index in breast cancer: targeting the tumor and modulation of enzyme expression.
Budman DR
Cancer Invest; 2002; 20 Suppl 2():38-44. PubMed ID: 12442348
[No Abstract] [Full Text] [Related]
6. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast cancer models.
Fujimoto-Ouchi K; Tanaka Y; Tominaga T
Clin Cancer Res; 2001 Apr; 7(4):1079-86. PubMed ID: 11309360
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and docetaxel in advanced breast cancer: analyses of a phase III comparative trial.
O'Shaughnessy J
Oncology (Williston Park); 2002 Oct; 16(10 Suppl 12):17-22. PubMed ID: 12435175
[TBL] [Abstract][Full Text] [Related]
8. Xeloda and Taxotere: a review of the development of the combination for use in metastatic breast cancer.
McDonald F; Miles D
Int J Clin Pract; 2003; 57(6):530-4. PubMed ID: 12918893
[TBL] [Abstract][Full Text] [Related]
9. Combination versus sequential single-agent therapy in metastatic breast cancer.
Miles D; von Minckwitz G; Seidman AD
Oncologist; 2002; 7 Suppl 6():13-9. PubMed ID: 12454315
[TBL] [Abstract][Full Text] [Related]
10. Exudative hyponychial dermatitis associated with capecitabine and docetaxel combination chemotherapy for metastatic breast carcinoma: report of three cases.
Chen GY; Chang TW; Chen WC
Br J Dermatol; 2003 May; 148(5):1071-3. PubMed ID: 12786853
[No Abstract] [Full Text] [Related]
11. Capecitabine in combination with docetaxel and epirubicin in patients with previously untreated, advanced breast carcinoma.
Venturini M; Durando A; Garrone O; Colozza MA; Contu A; Stevani I; Genta F; Bighin C; Lambiase A; Del Mastro L
Cancer; 2003 Mar; 97(5):1174-80. PubMed ID: 12599222
[TBL] [Abstract][Full Text] [Related]
12. [Docetaxel hydrate for treatment of advanced breast cancers].
Fujii H
Nihon Rinsho; 2000 Apr; 58 Suppl():254-8. PubMed ID: 11026003
[No Abstract] [Full Text] [Related]
13. [A case of breast cancer with brain metastases responding to paclitaxel and capecitabine therapy].
Sakaguchi K; Mizuta N; Imai A; Nakatsukasa K; Taguchi T
Gan To Kagaku Ryoho; 2012 Feb; 39(2):261-3. PubMed ID: 22333639
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.
Thomas ES
J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853
[No Abstract] [Full Text] [Related]
15. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
[TBL] [Abstract][Full Text] [Related]
16. CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations.
Prasad SR; Jhaveri KS; Saini S; Hahn PF; Halpern EF; Sumner JE
Radiology; 2002 Nov; 225(2):416-9. PubMed ID: 12409574
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma.
Han JY; Lee DH; Kim HY; Hong EK; Yoon SM; Chun JH; Lee HG; Lee SY; Shin EH; Lee JS
Cancer; 2003 Nov; 98(9):1918-24. PubMed ID: 14584075
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
19. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
